Based on these results, a contribution of the KLC1-ROS1 fusion-JAK2-STAT3-dependent machinery to enhance oncogenesis can be suggested, as well as the machinery being the therapeutic target of the KLC1-ROS1 fusion-harboring gliomas. This evidence concerns the gene ROS1 and central nervous system cancer.